A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Selinexor
Related studies linked through entity extraction aliases.
The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Karyopharm Expanded Access Program for Selinexor
- Status
- AVAILABLE
- Phase
- N/A
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Second-line Immunotherapy for ES-SCLC
- Status
- RECRUITING
- Phase
- NA
Using Tumor Models to Determine Treatments
- Status
- RECRUITING
- Phase
- PHASE2
Twice-per-weekSelinexor, 2 Days Melphalan
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2